Abstract

Nonadjacent immune cells communicate through a complex network of tunneling nanotubes (TNTs). TNTs can be hijacked by HIV-1, allowing it to spread between connected cells. Dendritic cells (DCs) are among the first cells to encounter HIV-1 at mucosal sites, but they are usually efficiently infected only at low levels. However, HIV-1 was demonstrated to productively infect DCs when the virus was complement-opsonized (HIV-C). Such HIV-C-exposed DCs mediated an improved antiviral and T-cell stimulatory capacity. The role of TNTs in combination with complement in enhancing DC infection with HIV-C remains to be addressed. To this aim, we evaluated TNT formation on the surface of DCs or DC/CD4+ T-cell co-cultures incubated with non- or complement-opsonized HIV-1 (HIV, HIV-C) and the role of TNTs or locally produced complement in the infection process using either two different TNT or anaphylatoxin receptor antagonists. We found that HIV-C significantly increased the formation of TNTs between DCs or DC/CD4+ T-cell co-cultures compared to HIV-exposed DCs or co-cultures. While augmented TNT formation in DCs promoted productive infection, as was previously observed, a significant reduction in productive infection was observed in DC/CD4+ T-cell co-cultures, indicating antiviral activity in this setting. As expected, TNT inhibitors significantly decreased infection of HIV-C-loaded-DCs as well as HIV- and HIV-C-infected-DC/CD4+ T-cell co-cultures. Moreover, antagonizing C5aR significantly inhibited TNT formation in DCs as well as DC/CD4+ T-cell co-cultures and lowered the already decreased productive infection in co-cultures. Thus, local complement mobilization via DC stimulation of complement receptors plays a pivotal role in TNT formation, and our findings herein might offer an exciting opportunity for novel therapeutic approaches to inhibit trans infection via C5aR targeting.

Highlights

  • With 1.5 million new infections in 2020 [1], the HIV-1 pandemic is far from over, with the genetic variability and the global diversity of the virus challenging the development of a curative treatment or vaccine [2]. the major targets of HIV-1 infection are CD4+ T cells, dendritic cells (DCs) play a crucial role in HIV-1 transmission and the shaping of adaptive immunity [3,4].DCs are among the first cells to encounter HIV-1 at the mucosal surface, where they act as a surveillance system, taking up antigens at the site of the infection [5]

  • The number of tunneling nanotubes (TNTs) displayed on DCs was counted 7 days postinfection, the same day when productive infection of co-cultures was analyzed, since TNT formation in DCs reaches its maximum at 7 dpi compared to earlier time points (Figure S1, Supplementary Materials)

  • As a negative control for TNT formation, DCs were subjected to the chronic inflammatory mediator PGE2 at the early stages of maturation, which is known to generate DCs that fail to reticulate when cultured with CD4+ T cells [52]

Read more

Summary

Introduction

DCs are among the first cells to encounter HIV-1 at the mucosal surface, where they act as a surveillance system, taking up antigens at the site of the infection [5]. Upon contact with the invading pathogen, DCs mature into potent antigen-presenting cells (APCs) and present the acquired antigen to naive CD4+ T cells either in mucosal tissue or after migrating to lymph nodes [6,7,8,9]. Despite DCs being a vehicle for trans infection, they only show low-level productive infection with HIV-1 due to a number of restriction factors [10,11]. Among the most potent restriction mechanisms of HIV-1 infection in DCs is SAM domain HD domain-containing protein 1 (SAMHD1) [12,13]. SAMHD1 blocks HIV-1 at the post-entry step by reducing the intracellular dNTP pool, depriving the virus of the required ‘building blocks’ for its replication [14,15,16]

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.